Materiały źródłowe

• #1 Granulomatosis With Polyangiitis (GPA, formerly Wegener’s)

  https://my.clevelandclinic.org/health/diseases/granulomatosis-with-polyangiitis-formerly-wegeners-granulomatosis

  Granulomatosis with polyangiitis can affect many parts of your body. Granulomatosis with polyangiitis primarily affects your kidneys and respiratory system (sinuses, nose, ears and lungs). But you may experience symptoms throughout your body. GPA affects your respiratory system and kidneys the most. But it can also affect many other organs and tissues, and how you feel overall. The smaller blood vessels that it targets travel throughout your body. GPA tends to affect your respiratory system and kidneys the most. Inflammation in your blood vessels can cause them to swell, break and bleed. It can also cause scarring that restricts the blood flow through your vessels, depriving your tissues of oxygen and nutrients. GPA can cause bleeding and organ damage in your renal and pulmonary systems (pulmonary-renal syndrome).

• #2 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/sites/books/NBK557827/

  Granulomatosis with polyangiitis is a rare form of vasculitis affecting small vessels. Hallmark features include necrotizing granulomas and pauci-immune vasculitis, most commonly affecting the upper respiratory tract, lungs, and kidneys. […] This activity describes the clinical presentation, evaluation, and treatment of granulomatosis with polyangiitis, highlighting the role of the interprofessional team in treating patients with this disease. […] Objectives: […] Implement evidence-based treatment protocols for managing granulomatosis with polyangiitis, including the use of immunosuppressive therapies. […] Collaborate with an interprofessional healthcare team, including rheumatologists, nephrologists, and pulmonologists, to provide comprehensive care for patients with granulomatosis with polyangiitis.

• #3 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557827/

  Granulomatosis with polyangiitis is a rare form of vasculitis affecting small vessels. Hallmark features include necrotizing granulomas and pauci-immune vasculitis, most commonly affecting the upper respiratory tract, lungs, and kidneys. […] This activity describes the clinical presentation, evaluation, and treatment of granulomatosis with polyangiitis, highlighting the role of the interprofessional team in treating patients with this disease. […] Objectives: […] Implement evidence-based treatment protocols for managing granulomatosis with polyangiitis, including the use of immunosuppressive therapies. […] Collaborate with an interprofessional healthcare team, including rheumatologists, nephrologists, and pulmonologists, to provide comprehensive care for patients with granulomatosis with polyangiitis.

• #4 Granulomatosis with Polyangiitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/granulomatosis-with-polyangiitis/

  Granulomatosis with polyangiitis (GPA) is a form of vasculitis, a family of rare disorders characterized by inflammation of the blood vessels, which can restrict blood flow and damage vital organs and tissues. GPA can worsen rapidly, so early diagnosis and treatment are essential to prevent organ damage or failure. […] GPA is a potentially serious but treatable disease. Glucocorticoids such as prednisone are used in combination with other medications that suppress the immune system to control inflammation. Even with effective treatment, relapse can occur, so ongoing medical follow-up is usually necessary. […] The choice of treatment for GPA depends on the organs affected and disease severity. Patients with milder disease are commonly prescribed glucocorticoids such as prednisone in combination with another medication such as methotrexate to control inflammation and induce remission of disease.

• #5 Granulomatosis with Polyangiitis (GPA) Signs & Symptoms | Rush

  https://www.rush.edu/conditions/granulomatosis-polyangiitis-gpa

  When you have granulomatosis with polyangiitis, an autoimmune disease that attacks your blood vessels, you can count on Rush for the expert care you need. […] A rare form of vasculitis, granulomatosis with polyangiitis (GPA) causes inflammation of the blood vessels in your nose, sinuses, throat, lungs and kidneys. GPA is an autoimmune disease, which means your immune system mistakenly attacks your blood vessels. […] If you are diagnosed with GPA, or your doctor suspects you have it, you will benefit from the expertise of a rheumatologist who specializes in autoimmune and musculoskeletal conditions. […] Your treatment will involve taking immunosuppressant medications to stop your immune system from attacking your blood vessels. […] With treatment, most patients recover; however, GPA returns in about half of all patients. […] The immunosuppressive medications you take to treat GPA can cause side effects, such as a higher risk of infection and bone loss. […] Treatment for GPA lasts two or more years. Our rheumatologists will be here for you the entire time, listening to your symptoms and responding to your concerns.

• #6 Pathology Outlines – Granulomatosis with polyangiitis (GPA)

  https://www.pathologyoutlines.com/topic/lungnontumorgranulomatosiswithpolyangiitis.html

  Granulomatosis with polyangiitis (GPA) is a systemic autoimmune vasculitis syndrome commonly involving the lower respiratory tract, the upper respiratory tract and the kidney. […] Characterized by a necrotizing vasculitis and a systemic granulomatous inflammatory process which replaces the involved tissues. […] Classic GPA clinicopathological triad includes vascular, respiratory and renal involvement. […] Histopathological features include necrotizing vasculitis of small to medium sized arteries and veins, eosinophilic palisading granulomas, and glomerulonephritis. […] Association with antineutrophil cytoplasmic antibodies (ANCA) positivity is noted, with C-ANCA being more specific for GPA. […] Typically, GPA manifests in the upper/lower respiratory tract and kidney; pulmonary symptoms/signs in the absence of upper respiratory symptoms/signs are unusual.

• #7 Granulomatosis with polyangiitis: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/000135.htm

  Granulomatosis with polyangiitis (GPA) is a rare disorder in which blood vessels become inflamed. This leads to damage in major organs of the body. It was formerly known as Wegener’s granulomatosis. […] GPA mainly causes inflammation of blood vessels in the lungs, kidneys, nose, sinuses, and ears. This is called vasculitis or angiitis. Other areas may also be affected in some cases. The disease can be fatal and prompt treatment is important. […] Because of the potentially serious nature of GPA, you may be hospitalized. Once the diagnosis is made, you will probably be treated with high doses of glucocorticoids (such as prednisone). These are given through the vein for 3 to 5 days at the beginning of treatment. Prednisone is given along with other medicines that slow down the immune response.

• #8 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  The mainstay of treatment for granulomatosis with polyangiitis (GPA) is a combination of corticosteroids and cytotoxic agents. Treatment should be tailored to appropriately treat GPA manifestations while minimizing long-term toxicities to the patient. Untreated generalized or severe GPA typically carries a dismal prognosis, with up to 90% of patients dying within 2 years, usually of respiratory or kidney failure. Even non-renal GPA carries a mortality rate of up to 40%. […] Outcomes for this previously fatal disease improved dramatically with the introduction in the 1970s of cyclophosphamide, which was administered in combination with corticosteroids. […] Approximately 90% of patients with GPA respond to cyclophosphamide, with approximately 75% experiencing complete remission. However, 30%-50% of those who initially respond experience at least one relapse, requiring another course of therapy.

• #9 Granulomatosis with polyangiitis (GPA) – Primary Care Notebook

  https://primarycarenotebook.com/pages/rheumatology/granulomatosis-with-polyangiitis-gpa

  Granulomatosis with polyangiitis (GPA) is an idiopathic vasculitis of medium and small arteries, characterized by necrotizing granulomatous inflammation. […] This disease is generally characterized by antineutrophil cytoplasm antibodies (ANCA) – however there are rare cases with negative ANCA. […] disease generally develops over a period of time with the mean period from onset of symptoms to diagnosis ranging from 4.7 to 15 months. […] without treatment it is invariably fatal. […] standard treatment procedure is divided into two essential phases, induction and maintenance. […] induction phase is based on combination of systemic corticosteroid and immunosuppressant therapy. […] maintenance phase comprises corticosteroids and azathioprine/methotrexate supplementation. […] surgical treatment ought to be considered for patients who are not responding to pharmacotherapy.

• #10 ENT manifestations of Granulomatosis with polyangiitis

  https://www.oaepublish.com/articles/2574-1209.2021.52

  Ear, nose, and throat (ENT) symptoms represent the most frequent manifestations at the onset of granulomatosis with polyangiitis (GPA). […] The burden of diagnosing a limited disease with localized manifestations in the upper aerodigestive tract rests mainly with the otolaryngologist. […] ENT surgeons play a key role in early GPA diagnosis and treatment in collaboration with rheumatologists, pulmonologists, and nephrologists if needed, especially in GPA cases with negative ANCA antibodies, the diagnosis of which is often more challenging and delayed. […] Approximately 63% of GPA patients present with rhinogenic, otologic, or laryngopharyngeal manifestations. […] Symptoms of chronic sinusitis are the most common initial complaint in GPA. Sino-nasal involvement in GPA is often misdiagnosed as chronic sinusitis or rhinitis that fails to respond to the initial conventional therapy.

• #11 Granulomatosis with Polyangiitis (GPA) – Johns Hopkins Vasculitis Center

  https://www.hopkinsvasculitis.org/types-vasculitis/granulomatosis-with-polyangiitis/

  Granulomatosis with Polyangiitis is nearly equally distributed between the sexes, with a slight male predominance. Granulomatosis with Polyangiitis typically occurs in middle age, but is found in people of all ages. Although it is unusual for Granulomatosis with Polyangiitis to occur in childhood, it is not unusual for a Granulomatosis with Polyangiitis patient to be in his/her 70s or even 80s at the time of diagnosis. […] Granulomatosis with Polyangiitis can affect virtually any site in the body, but it has a predisposition for certain organs. The classic organs involved in Granulomatosis with Polyangiitis are the upper respiratory tract (sinuses, nose, ears, and trachea [the windpipe]), the lungs, and the kidneys. […] Granulomatosis with Polyangiitis involvement of nearly all organs has been described, including the meninges (the layers of protective tissue around the brain and spinal cord), the prostate gland, and the genitourinary tract. In addition to involving specific organs, Granulomatosis with Polyangiitis also commonly results in generalized symptoms of fatigue, low-grade fever, and weight loss.

• #12 Pathology Outlines – Granulomatosis with polyangiitis (GPA)

  https://www.pathologyoutlines.com/topic/lungnontumorgranulomatosiswithpolyangiitis.html

  Most common presenting symptoms/signs (local) include rhinorrhea, purulent/bloody nasal discharge, oral or nasal ulcers, sinus pain, cough, hemoptysis, and chest pain. […] Most common presenting symptoms/signs (systemic) include polyarthralgias, myalgias, fever, malaise, and weight loss. […] Diagnosis involves clinical setting, corresponding sites of pathology, symptoms, radiological findings, and patient demographics, along with positive ELISA serum C-ANCA test or less commonly P-ANCA test. […] Biopsy or resection shows characteristic histologic findings consistent with GPA. […] Usually treated with corticosteroids and cyclophosphamide with excellent prognosis; recent addition of rituximab for poorly responding cases or relapses is suggested. […] Methotrexate serves as effective maintenance therapy for mild/limited GPA.

• #13 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  The mainstay of treatment for granulomatosis with polyangiitis (GPA) is a combination of corticosteroids and cytotoxic agents. Treatment should be tailored to appropriately treat GPA manifestations while minimizing long-term toxicities to the patient. Untreated generalized or severe GPA typically carries a dismal prognosis, with up to 90% of patients dying within 2 years, usually of respiratory or kidney failure. Even non-renal GPA carries a mortality rate of up to 40%. […] Outcomes for this previously fatal disease improved dramatically with the introduction in the 1970s of cyclophosphamide, which was administered in combination with corticosteroids. […] Approximately 90% of patients with GPA respond to cyclophosphamide, with approximately 75% experiencing complete remission. However, 30%-50% of those who initially respond experience at least one relapse, requiring another course of therapy.

• #14 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  The mainstay of treatment for granulomatosis with polyangiitis (GPA) is a combination of corticosteroids and cytotoxic agents. Treatment should be tailored to appropriately treat GPA manifestations while minimizing long-term toxicities to the patient. Untreated generalized or severe GPA typically carries a dismal prognosis, with up to 90% of patients dying within 2 years, usually of respiratory or kidney failure. Even non-renal GPA carries a mortality rate of up to 40%. […] Outcomes for this previously fatal disease improved dramatically with the introduction in the 1970s of cyclophosphamide, which was administered in combination with corticosteroids. […] Approximately 90% of patients with GPA respond to cyclophosphamide, with approximately 75% experiencing complete remission. However, 30%-50% of those who initially respond experience at least one relapse, requiring another course of therapy.

• #15 Granulomatosis with polyangiitis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/granulomatosis-with-polyangiitis/diagnosis-treatment/drc-20351093

  Diagnosis involves the steps that your healthcare team takes to find out if you have granulomatosis with polyangiitis (GPA). Your healthcare professional asks you about your symptoms and health history. You also get a physical exam. You may need other tests as well. […] Treatment for granulomatosis with polyangiitis (GPA) includes medicines to get the disease under control and keep it from coming back. Along with getting care from your regular healthcare professional, you’ll likely need treatment and follow-up care from various specialists. The specialists that you need depend on the organs that the disease affects. With early treatment, many people who have GPA get better and lead full lives. […] You’re likely to get better after treatment for granulomatosis with polyangiitis (GPA). Even so, you might feel stress about the disease coming back or the damage it can cause. Here are some tips to help you cope: Understand your condition. Learn all that you can about GPA. The knowledge may help you deal with complications, medicine side effects and relapses. Talk with your healthcare professional. You also might want to talk with a counselor or a medical social worker. […] A specialist likely will be the one to find out if you have granulomatosis with polyangiitis.

• #16 Granulomatosis with Polyangiitis | Conditions & Treatments | UR Medicine

  https://www.urmc.rochester.edu/conditions-and-treatments/granulomatosis-with-polyangiitis

  Granulomatosis with polyangiitis (GPA), formerly called Wegener’s granulomatosis, is an autoimmune disorder that causes inflammation, swelling, and irritation in blood vessels and other tissues. […] This inflammation reduces or stops the flow of blood to organs in the body. The condition mostly affects the respiratory system, including the sinuses, nose, windpipe, and lungs. It can also affect the kidneys and other organs in the body. […] Ongoing GPA can have serious complications. […] Since this disease affects many parts of the body, more than one specialist may be involved in diagnosing and managing your illness. Specialists may include a pulmonologist (lungs), nephrologist (kidneys) and rheumatologist (autoimmune diseases). […] To diagnose GPA, medical professionals will first take a detailed medical history and carry out a physical examination. They will then order various diagnostic tests, such as blood work, urine studies, and imaging tests. In some cases, a kidney biopsy may be warranted. While these tests can help to rule out other potential causes of your symptoms, a biopsy which involves examining a tissue sample is the only way to definitely diagnose GPA.

• #17 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557827/

  The treatment of GPA involves the use of immunosuppressive agents in a variety of combinations. Treatment is classified into 2 phases – the induction phase and the maintenance phase. Commonly used agents are cyclophosphamide, glucocorticoids, rituximab, azathioprine, methotrexate, and plasmapheresis if indicated. […] For maintenance of remission, rituximab is recommended. Azathioprine or methotrexate can also be considered, but their use should be reserved for patients with eGFR more than 60 mL/min/1.73m2. […] Providing patient-centered care for individuals with GPA requires a collaborative effort among healthcare professionals, including clinicians, advanced practice practitioners, pharmacists, and other healthcare providers. […] Effective communication among these team members is key to successful patient care. Nurses are critical in monitoring vital checks and measuring urine output. They also provide immediate care to the patient and monitor them closely during infusions for adverse effects.

• #18 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis): Practice Essentials, Background, Etiology

  https://emedicine.medscape.com/article/332622-overview

  Granulomatosis with polyangiitis (GPA), formerly known as Wegener granulomatosis, is a rare multisystem autoimmune disease of unknown etiology. GPA is one of the antineutrophil cytoplasmic antibody (ANCA) associated vasculitic disorders, which can affect the ears, nose, throat, respiratory tract, skin, kidneys, and peripheral nervous system. Its hallmark features include necrotizing granulomatous inflammation and pauci-immune vasculitis in small- and medium-sized blood vessels. […] The diagnosis of GPA should be suspected when a patient has constitutional symptoms with evidence of renal involvement, respiratory tract involvement (upper or lower), mononeuropathy, or new skin rashes. […] Routine laboratory tests are nonspecific in GPA. Results may include abnormal kidney function tests and urinalysis in patients with kidney involvement; urinary sediment with more than 5 RBCs per HPF or erythrocyte casts.

• #19 Granulomatosis with Polyangiitis (GPA) – Johns Hopkins Vasculitis Center

  https://www.hopkinsvasculitis.org/types-vasculitis/granulomatosis-with-polyangiitis/

  A large, multi-center study demonstrated that Bactrim is useful in preventing flares of Granulomatosis with Polyangiitis in the upper respiratory tract. […] The diagnosis of Granulomatosis with Polyangiitis is established most securely by biopsy specimens showing the triad of vasculitis, granulomata, and large areas of necrosis (known as geographic necrosis) admixed with acute and chronic inflammatory cells. […] However, more easily obtained biopsy specimens of the nose, or sinuses may show several of the changes that are highly suggestive of Granulomatosis with Polyangiitis. […] With the traditional treatment of prednisone and cyclophosphamide, more than 90% of patients improve and 75% remit. However, 50% of the patients who later remit also relapse, and oral daily cyclophosphamide causes serious toxicity. […] Weekly, methotrexate appears to be an effective alternative for Granulomatosis with Polyangiitis that is not immediately life-threatening, and it also appears to be beneficial in maintaining remission.

• #20 Granulomatosis with Polyangiitis (GPA) – Johns Hopkins Vasculitis Center

  https://www.hopkinsvasculitis.org/types-vasculitis/granulomatosis-with-polyangiitis/

  Whenever possible, it is important to confirm the diagnosis of Granulomatosis with Polyangiitis by biopsying an involved organ and finding the pathologic features of this disease under the microscope. […] Lung biopsy (either open or thoracoscopic) is often the best way of diagnosing Granulomatosis with Polyangiitis. […] Until the 1970s, Granulomatosis with Polyangiitis was nearly always a fatal condition. […] The first use of cyclophosphamide in the late 1960s began to change the terrible prognosis of this disease. Using the combination of cyclophosphamide and prednisone, more than 90% of patients with severe disease respond to treatment, and 75% are able to achieve disease remissions. […] During the 1990s, physicians have increasingly used the combination of methotrexate and prednisone rather than cyclophosphamide and prednisone for Granulomatosis with Polyangiitis patients who do not have immediately life-threatening disease.

• #21 Granulomatosis with Polyangiitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/granulomatosis-with-polyangiitis/

  Patients with severe disease may be prescribed the biologic drug rituximab, used in conjunction with glucocorticoids. […] Once the disease is in remission, patients will need to continue taking maintenance medications such as azathioprine, methotrexate or rituximab, to keep the disease under control. […] GPA is a chronic disease with periods of relapse and remission. If your initial symptoms return or you develop new ones, report them to your doctor as soon as possible. Regular doctor visits and ongoing monitoring of laboratory and imaging tests are important in detecting relapses early. […] Effective treatment of GPA may require the coordinated efforts and ongoing care of a team of medical providers and specialists. In addition to a primary care provider, GPA patients may need to see the following specialists: Rheumatologist, Pulmonologist, Otolaryngologist, Nephrologist, Dermatologist, Cardiologist, Neurologist.

• #22 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  Current treatment recommendations in GPA depend on the severity and activity of disease. […] GPA is a multisystem disease that requires a multidisciplinary approach to management, involving rheumatologists, pulmonologists, nephrologists, and otolaryngologists (ear, nose, and throat specialists). […] Remission is defined as the absence of clinical signs or symptoms attributed to GPA on or off immunosuppressive therapy. […] Once induction of remission has occurred, treatment for maintenance of remission should be continued for at least 18 months, often longer. […] Agents that can be used in remission maintenance include methotrexate, rituximab, azathioprine, mycophenolate mofetil, and leflunomide. […] The choice of remission maintenance therapy is influenced by disease severity and certain patient-specific factors.

• #23 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/sites/books/NBK557827/

  The treatment of GPA involves the use of immunosuppressive agents in a variety of combinations. Treatment is classified into 2 phases – the induction phase and the maintenance phase. Commonly used agents are cyclophosphamide, glucocorticoids, rituximab, azathioprine, methotrexate, and plasmapheresis if indicated. […] For maintenance of remission, rituximab is recommended. Azathioprine or methotrexate can also be considered, but their use should be reserved for patients with eGFR more than 60 mL/min/1.73m2. […] Providing patient-centered care for individuals with GPA requires a collaborative effort among healthcare professionals, including clinicians, advanced practice practitioners, pharmacists, and other healthcare providers. […] Effective communication among these team members is key to successful patient care. Nurses are critical in monitoring vital checks and measuring urine output. They also provide immediate care to the patient and monitor them closely during infusions for adverse effects.

• #24 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557827/

  The treatment of GPA involves the use of immunosuppressive agents in a variety of combinations. Treatment is classified into 2 phases – the induction phase and the maintenance phase. Commonly used agents are cyclophosphamide, glucocorticoids, rituximab, azathioprine, methotrexate, and plasmapheresis if indicated. […] For maintenance of remission, rituximab is recommended. Azathioprine or methotrexate can also be considered, but their use should be reserved for patients with eGFR more than 60 mL/min/1.73m2. […] Providing patient-centered care for individuals with GPA requires a collaborative effort among healthcare professionals, including clinicians, advanced practice practitioners, pharmacists, and other healthcare providers. […] Effective communication among these team members is key to successful patient care. Nurses are critical in monitoring vital checks and measuring urine output. They also provide immediate care to the patient and monitor them closely during infusions for adverse effects.

• #25 New Granulomatosis with polyangiitis (Werner’s) treatments 2025 | Everyone.org

  https://everyone.org/explore/treatment/?id=45

  Standard treatment for GPA typically involves a two-phase approach: induction therapy to achieve remission and maintenance therapy to sustain remission and prevent relapse. Induction therapy often involves potent immunosuppressive medications such as corticosteroids combined with cyclophosphamide or rituximab. Maintenance therapy usually includes less aggressive immunosuppressive medications such as azathioprine, methotrexate, or mycophenolate mofetil. […] Ultimately, treatment decisions should be individualized, considering the patient’s clinical presentation, preferences, and potential risks and benefits of each therapy. Patients should engage in thorough discussions with their healthcare providers to determine the most appropriate treatment regimen tailored to their specific needs and circumstances.

• #26 Granulomatosis with polyangiitis (GPA)

  https://www.nhs.uk/conditions/granulomatosis-with-polyangiitis/

  Granulomatosis with polyangiitis (GPA) is a rare condition where blood vessels become inflamed, mainly in the ears, nose, sinuses, kidneys and lungs. It can be serious if not treated but medicines can help manage the symptoms. […] If you have been diagnosed with GPA, and have new or returning symptoms, see the specialist treating you. […] You’ll be treated by a specialist if you have granulomatosis with polyangiitis (GPA). […] Treatment depends on how severe it is and the body parts affected. […] If you have mild GPA, you may be given an anti-inflammatory medicine called a steroid to control your symptoms. […] If you have severe GPA, you may be given a biological medicine such as rituximab or avacopan, or both, along with steroids. […] In very severe cases that affect the kidneys, you may need dialysis or a kidney transplant. […] If you have granulomatosis with polyangiitis (GPA), your care team will pass information on to the National Congenital Anomaly and Rare Disease Registration Service (NCARDRS).

• #27 New Granulomatosis with polyangiitis (Werner’s) treatments 2025 | Everyone.org

  https://everyone.org/explore/treatment/?id=45

  Initial treatment for GPA usually involves aggressive immunosuppressive therapy aimed at rapidly controlling inflammation and preventing irreversible organ damage. The standard induction therapy typically includes corticosteroids combined with immunosuppressive agents such as cyclophosphamide or rituximab. These medications help suppress the immune system’s abnormal response, thereby reducing inflammation and disease activity. […] Once remission is achieved, maintenance therapy is essential to prevent disease relapse. Maintenance therapy typically involves less aggressive immunosuppressive medications, including methotrexate, azathioprine, mycophenolate mofetil, or rituximab administered at lower doses or less frequent intervals. The choice of maintenance therapy is individualized based on patient-specific factors, including tolerance, side-effect profiles, and previous treatment responses.

• #28 Granulomatosis with Polyangiitis (GPA) | STROKE MANUAL

  https://www.stroke-manual.com/granulomatosis-with-polyangiitis-gpa/

  granulomatosis with polyangiitis (GPA) is a necrotizing, granulomatous vasculitis primarily affecting small vessels in the upper respiratory tract, lungs, and kidneys; neurologic symptoms, including stroke, are relatively rare (7%) […] GPA belongs to a spectrum of disorders known as ANCA-associated vasculitides (AAV), which includes other conditions like microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) […] treatment involves the use of immunosuppressive agents in different combinations […] treatment decisions are based on the classification of patients according to the severity of their disease […] severe disease (a life-threatening disease or organ-threatening disease) warrants the use of cyclophosphamide […] treatment is divided into 2 phases: induction phase (aims to control active disease and reduce inflammation) and maintenance (to prevent relapse)

• #29 Granulomatosis with polyangiitis (GPA)

  https://www.nhs.uk/conditions/granulomatosis-with-polyangiitis/

  Granulomatosis with polyangiitis (GPA) is a rare condition where blood vessels become inflamed, mainly in the ears, nose, sinuses, kidneys and lungs. It can be serious if not treated but medicines can help manage the symptoms. […] If you have been diagnosed with GPA, and have new or returning symptoms, see the specialist treating you. […] You’ll be treated by a specialist if you have granulomatosis with polyangiitis (GPA). […] Treatment depends on how severe it is and the body parts affected. […] If you have mild GPA, you may be given an anti-inflammatory medicine called a steroid to control your symptoms. […] If you have severe GPA, you may be given a biological medicine such as rituximab or avacopan, or both, along with steroids. […] In very severe cases that affect the kidneys, you may need dialysis or a kidney transplant. […] If you have granulomatosis with polyangiitis (GPA), your care team will pass information on to the National Congenital Anomaly and Rare Disease Registration Service (NCARDRS).

• #30 Granulomatosis with Polyangiitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/granulomatosis-with-polyangiitis/

  Granulomatosis with polyangiitis (GPA) is a form of vasculitis, a family of rare disorders characterized by inflammation of the blood vessels, which can restrict blood flow and damage vital organs and tissues. GPA can worsen rapidly, so early diagnosis and treatment are essential to prevent organ damage or failure. […] GPA is a potentially serious but treatable disease. Glucocorticoids such as prednisone are used in combination with other medications that suppress the immune system to control inflammation. Even with effective treatment, relapse can occur, so ongoing medical follow-up is usually necessary. […] The choice of treatment for GPA depends on the organs affected and disease severity. Patients with milder disease are commonly prescribed glucocorticoids such as prednisone in combination with another medication such as methotrexate to control inflammation and induce remission of disease.

• #31 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  The combination of cyclophosphamide and glucocorticoids remained the recommended therapy for induction of remission in generalized/severe GPA for years. […] In 2011, however, the US Food and Drug Administration (FDA) approved the use of rituximab, a monoclonal antibody that targets B cells, in combination with steroids, for induction of remission in GPA (and microscopic polyangiitis). […] Because rituximab has been shown to be as effective as cyclophosphamide and is considered less toxic, in 2021, the American College of Rheumatology/Vasculitis Foundation guidelines conditionally recommended rituximab over cyclophosphamide for remission induction in patients with active, severe GPA. […] In general, limited disease does not require as aggressive therapy as does severe disease. Additionally, treatment recommendations are different for induction of remission and maintenance of remission.

• #32 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis): Practice Essentials, Background, Etiology

  https://emedicine.medscape.com/article/332622-overview

  Induction of remission in GPA is approached as follows: In organ- or life-threatening disease: Rituximab or cyclophosphamide in combination with glucocorticoids; rituximab is preferred over cyclophosphamide. […] Once induction of remission has occurred, treatment for maintenance of remission should be continued for at least 18 months, often longer; hazard ratio for relapse is reduced by 29% when maintenance treatment is continued for 18 months, and by 66% when it is continued for 36 months. […] Patients with GPA and their families must be educated on the serious nature of this disease. Potential risks and adverse effects of immunosuppressive medications should be detailed.

• #33 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  The combination of cyclophosphamide and glucocorticoids remained the recommended therapy for induction of remission in generalized/severe GPA for years. […] In 2011, however, the US Food and Drug Administration (FDA) approved the use of rituximab, a monoclonal antibody that targets B cells, in combination with steroids, for induction of remission in GPA (and microscopic polyangiitis). […] Because rituximab has been shown to be as effective as cyclophosphamide and is considered less toxic, in 2021, the American College of Rheumatology/Vasculitis Foundation guidelines conditionally recommended rituximab over cyclophosphamide for remission induction in patients with active, severe GPA. […] In general, limited disease does not require as aggressive therapy as does severe disease. Additionally, treatment recommendations are different for induction of remission and maintenance of remission.

• #34 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  Current treatment recommendations in GPA depend on the severity and activity of disease. […] GPA is a multisystem disease that requires a multidisciplinary approach to management, involving rheumatologists, pulmonologists, nephrologists, and otolaryngologists (ear, nose, and throat specialists). […] Remission is defined as the absence of clinical signs or symptoms attributed to GPA on or off immunosuppressive therapy. […] Once induction of remission has occurred, treatment for maintenance of remission should be continued for at least 18 months, often longer. […] Agents that can be used in remission maintenance include methotrexate, rituximab, azathioprine, mycophenolate mofetil, and leflunomide. […] The choice of remission maintenance therapy is influenced by disease severity and certain patient-specific factors.

• #35 Granulomatosis with polyangiitis: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/000135.htm

  With treatment, the outlook for most patients is good. Most people who receive corticosteroids and other medicines that slow the immune response get much better. Most people with GPA are treated with ongoing medicines to prevent relapse for at least 12 to 24 months. […] Complications most often occur when the disease is not treated. People with GPA develop tissue damage in the lungs, airways, and the kidneys. Kidney involvement may result in blood in the urine and kidney failure. Kidney disease can quickly get worse. Kidney function may not improve, even when the condition is controlled by medicines. […] Contact your provider if: You develop chest pain and shortness of breath. You cough up blood. You have blood in your urine. You have other symptoms of this disorder.

• #36 Granulomatosis with Polyangiitis (GPA) | STROKE MANUAL

  https://www.stroke-manual.com/granulomatosis-with-polyangiitis-gpa/

  the duration of maintenance therapy is usually 12-24 (36) months […] oral corticosteroids + methotrexate, azathioprine, or rituximab are used […] the choice of maintenance therapy is determined based on the patients individual response to treatment and their specific risk factors and comorbidities […] prognosis depends on the degree of renal impairment and whether therapy is initiated early […] early initiation of therapy can significantly improve the prognosis; 80-90% of patients survive 5 years and are able to lead a relatively normal life […] untreated disease has a poor prognosis; up to 70% of patients die within 1 year […] granulomatosis is prone to relapses; which can occur in up to 50% of patients, sometimes several years after the initial diagnosis; relapses may be triggered by infections or reductions in corticosteroid doses.

• #37 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  In patients with severe GPA who achieve remission after induction immunosuppressive therapy (rituximab or cyclophosphamide), rituximab is preferred for maintenance therapy, over azathioprine, methotrexate, or mycophenolate. […] Patients with non-severe GPA who achieve remission with methotrexate can be continued on it for maintenance, or rituximab may be replaced with azathioprine, mycophenolate, or leflunomide. […] The addition of TMP-SMZ (800/160 mg twice daily) to standard maintenance therapy may reduce the rate of relapse in GPA.

• #38 Granulomatosis with Polyangiitis (GPA) – EyeWiki

  https://eyewiki.org/Granulomatosis_with_Polyangiitis_(GPA)

  Upon achieving a significant response (prior to remission) with the above treatment, one should begin tapering the dose of glucocorticoids. […] For maintenance of remission, rituximab, azathioprine, and methotrexate are the recommended options. […] Prior to immunosuppressive therapy, GPA was fatal with a mean survival rate of 5 months, when left untreated. With corticosteroid therapy alone, the mean survival increased to 12.5 months. […] Traditional therapies of combination prednisone and cyclophosphamide result in 90% of patients experiencing some symptomatic improvement and remission in 75%.

• #39 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  In patients with severe GPA who achieve remission after induction immunosuppressive therapy (rituximab or cyclophosphamide), rituximab is preferred for maintenance therapy, over azathioprine, methotrexate, or mycophenolate. […] Patients with non-severe GPA who achieve remission with methotrexate can be continued on it for maintenance, or rituximab may be replaced with azathioprine, mycophenolate, or leflunomide. […] The addition of TMP-SMZ (800/160 mg twice daily) to standard maintenance therapy may reduce the rate of relapse in GPA.

• #40 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557827/

  The treatment of GPA involves the use of immunosuppressive agents in a variety of combinations. Treatment is classified into 2 phases – the induction phase and the maintenance phase. Commonly used agents are cyclophosphamide, glucocorticoids, rituximab, azathioprine, methotrexate, and plasmapheresis if indicated. […] For maintenance of remission, rituximab is recommended. Azathioprine or methotrexate can also be considered, but their use should be reserved for patients with eGFR more than 60 mL/min/1.73m2. […] Providing patient-centered care for individuals with GPA requires a collaborative effort among healthcare professionals, including clinicians, advanced practice practitioners, pharmacists, and other healthcare providers. […] Effective communication among these team members is key to successful patient care. Nurses are critical in monitoring vital checks and measuring urine output. They also provide immediate care to the patient and monitor them closely during infusions for adverse effects.

• #41 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/sites/books/NBK557827/

  The treatment of GPA involves the use of immunosuppressive agents in a variety of combinations. Treatment is classified into 2 phases – the induction phase and the maintenance phase. Commonly used agents are cyclophosphamide, glucocorticoids, rituximab, azathioprine, methotrexate, and plasmapheresis if indicated. […] For maintenance of remission, rituximab is recommended. Azathioprine or methotrexate can also be considered, but their use should be reserved for patients with eGFR more than 60 mL/min/1.73m2. […] Providing patient-centered care for individuals with GPA requires a collaborative effort among healthcare professionals, including clinicians, advanced practice practitioners, pharmacists, and other healthcare providers. […] Effective communication among these team members is key to successful patient care. Nurses are critical in monitoring vital checks and measuring urine output. They also provide immediate care to the patient and monitor them closely during infusions for adverse effects.

• #42 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557827/

  Patients often face fatigue, pain, disease-related complications, medication side effects, and emotional stress, all of which can significantly impact their well-being, work, and personal relationships. […] Keeping a journal to track medications and appointments can be a helpful tool in managing the complexities of the condition.

• #43 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/sites/books/NBK557827/

  Living with GPA can be extremely challenging. Patients often face fatigue, pain, disease-related complications, medication side effects, and emotional stress, all of which can significantly impact their well-being, work, and personal relationships. […] Due to the multisystemic nature of GPA, patients typically require care from multiple healthcare providers, making it crucial to adhere to follow-up appointments and treatment plans.

• #44 Granulomatosis with polyangiitis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/granulomatosis-with-polyangiitis/diagnosis-treatment/drc-20351093

  Diagnosis involves the steps that your healthcare team takes to find out if you have granulomatosis with polyangiitis (GPA). Your healthcare professional asks you about your symptoms and health history. You also get a physical exam. You may need other tests as well. […] Treatment for granulomatosis with polyangiitis (GPA) includes medicines to get the disease under control and keep it from coming back. Along with getting care from your regular healthcare professional, you’ll likely need treatment and follow-up care from various specialists. The specialists that you need depend on the organs that the disease affects. With early treatment, many people who have GPA get better and lead full lives. […] You’re likely to get better after treatment for granulomatosis with polyangiitis (GPA). Even so, you might feel stress about the disease coming back or the damage it can cause. Here are some tips to help you cope: Understand your condition. Learn all that you can about GPA. The knowledge may help you deal with complications, medicine side effects and relapses. Talk with your healthcare professional. You also might want to talk with a counselor or a medical social worker. […] A specialist likely will be the one to find out if you have granulomatosis with polyangiitis.

• #45 Granulomatosis with Polyangiitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/granulomatosis-with-polyangiitis/

  Living with a chronic disease such as GPA can be challenging at times. Fatigue, pain, emotional stress, and medication side effects can take a toll on your sense of well-being, affecting relationships, work, and other aspects of your daily life. […] There is no cure for GPA at this time, but early diagnosis and effective treatment can bring the disease into remission, and many patients can lead full, productive lives. Left untreated, GPA can lead to potentially life-threatening organ damage or failure. Even with treatment, many patients will experience periods of relapse, so ongoing medical care is important.

• #46 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  The mainstay of treatment for granulomatosis with polyangiitis (GPA) is a combination of corticosteroids and cytotoxic agents. Treatment should be tailored to appropriately treat GPA manifestations while minimizing long-term toxicities to the patient. Untreated generalized or severe GPA typically carries a dismal prognosis, with up to 90% of patients dying within 2 years, usually of respiratory or kidney failure. Even non-renal GPA carries a mortality rate of up to 40%. […] Outcomes for this previously fatal disease improved dramatically with the introduction in the 1970s of cyclophosphamide, which was administered in combination with corticosteroids. […] Approximately 90% of patients with GPA respond to cyclophosphamide, with approximately 75% experiencing complete remission. However, 30%-50% of those who initially respond experience at least one relapse, requiring another course of therapy.

• #47 Granulomatosis with Polyangiitis (Wegener’s)

  https://rheumatology.org/patients/granulomatosis-with-polyangiitis-wegeners

  Granulomatosis with polyangiitis (GPA), formerly called Wegeners granulomatosis, is a rare blood vessel disease. Its a type of vasculitis, or inflammation of the blood vessels, specifically small- and medium-sized blood vessels causing an inability of blood to flow properly and deliver oxygen to cells around the body. GPA can lead to kidney or lung failure without prompt treatment. Treatment choice depends on the organs involved, disease severity and a persons overall health and may include steroid, disease modifying rheumatic drugs (DMARDs), chemotherapy, or biologic based treatment as determined by their rheumatology healthcare provider. People with GPA need regular check-ups, as disease relapses are common. It can also have serious complications that are even life-threatening if not treated promptly. Patients need regular laboratory tests, imaging scans and clinical visits with a rheumatology provider. […] Regular rheumatology visits and testing should spot any problems early so that prompt, effective treatment can be started.

• #48 Granulomatosis with polyangiitis (Wegener’s granulomatosis)

  https://patient.info/doctor/granulomatosis-with-polyangiitis-wegeners-granulomatosis-pro

  Aggressive immunosuppressive therapy is required to control pulmonary and renal involvement. Plasma exchange is sometimes used as an adjunct in these circumstances. […] Once the patient is in remission, cyclophosphamide should be replaced by azathioprine or methotrexate. Leflunomide or mycophenolate may be given as alternatives if there is intolerance or lack of efficacy. […] Relapses should be treated by increasing prednisolone and optimising immunosuppressive therapy. Plasma exchange may be needed. Triggers for relapse (eg, infection, malignancy, change in drug therapy) should be considered. […] The treatment of refractory cases remains a challenge. Rituximab is more effective than cyclophosphamide in these circumstances. Triggers should be considered and the diagnosis reviewed.

• #49 Granulomatosis with Polyangiitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/granulomatosis-with-polyangiitis/

  Patients with severe disease may be prescribed the biologic drug rituximab, used in conjunction with glucocorticoids. […] Once the disease is in remission, patients will need to continue taking maintenance medications such as azathioprine, methotrexate or rituximab, to keep the disease under control. […] GPA is a chronic disease with periods of relapse and remission. If your initial symptoms return or you develop new ones, report them to your doctor as soon as possible. Regular doctor visits and ongoing monitoring of laboratory and imaging tests are important in detecting relapses early. […] Effective treatment of GPA may require the coordinated efforts and ongoing care of a team of medical providers and specialists. In addition to a primary care provider, GPA patients may need to see the following specialists: Rheumatologist, Pulmonologist, Otolaryngologist, Nephrologist, Dermatologist, Cardiologist, Neurologist.

• #50 Granulomatosis with Polyangiitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/granulomatosis-with-polyangiitis/

  Patients with severe disease may be prescribed the biologic drug rituximab, used in conjunction with glucocorticoids. […] Once the disease is in remission, patients will need to continue taking maintenance medications such as azathioprine, methotrexate or rituximab, to keep the disease under control. […] GPA is a chronic disease with periods of relapse and remission. If your initial symptoms return or you develop new ones, report them to your doctor as soon as possible. Regular doctor visits and ongoing monitoring of laboratory and imaging tests are important in detecting relapses early. […] Effective treatment of GPA may require the coordinated efforts and ongoing care of a team of medical providers and specialists. In addition to a primary care provider, GPA patients may need to see the following specialists: Rheumatologist, Pulmonologist, Otolaryngologist, Nephrologist, Dermatologist, Cardiologist, Neurologist.

• #51 Granulomatosis with Polyangiitis (GPA) Signs & Symptoms | Rush

  https://www.rush.edu/conditions/granulomatosis-polyangiitis-gpa

  When you have granulomatosis with polyangiitis, an autoimmune disease that attacks your blood vessels, you can count on Rush for the expert care you need. […] A rare form of vasculitis, granulomatosis with polyangiitis (GPA) causes inflammation of the blood vessels in your nose, sinuses, throat, lungs and kidneys. GPA is an autoimmune disease, which means your immune system mistakenly attacks your blood vessels. […] If you are diagnosed with GPA, or your doctor suspects you have it, you will benefit from the expertise of a rheumatologist who specializes in autoimmune and musculoskeletal conditions. […] Your treatment will involve taking immunosuppressant medications to stop your immune system from attacking your blood vessels. […] With treatment, most patients recover; however, GPA returns in about half of all patients. […] The immunosuppressive medications you take to treat GPA can cause side effects, such as a higher risk of infection and bone loss. […] Treatment for GPA lasts two or more years. Our rheumatologists will be here for you the entire time, listening to your symptoms and responding to your concerns.

• #52 Granulomatosis with Polyangiitis | Rheumatology & Clinical Research located in North Houston, Tomball, TX | Rheumatology Clinic of Houston

  https://www.houstonrheumatology.com/content/granulomatosis-with-polyangiitis

  All of the medications used to treat GPA have significant side effects to consider. Minimizing or preventing the risk of serious side effects is an important part of caring for someone with GPA. […] The impact of GPA can vary greatly, depending on its severity, the organs involved, and any complications related to the disease or its treatment. People with GPA need ongoing checkups that include laboratory studies, imaging tests, and clinic visits with their doctor. Such monitoring is essential to follow the course of GPA and to detect or prevent short- or long-term treatment-related complications. […] Even with effective treatment, recurrences (relapses) are common. Relapses may resemble or differ from the initial onset, so new symptoms should be reported to the medical practitioner as soon as possible. Regular doctor visits together with monitoring of laboratory tests and imaging studies can help to detect relapses early.

• #53 Granulomatosis with Polyangiitis | Cedars-Sinai

  https://www.cedars-sinai.org/health-library/diseases-and-conditions/g/granulomatosis-with-polyangiitis.html

  Granulomatosis with polyangiitis (GPA) is an autoimmune disorder. An autoimmune disorder occurs when the body’s immune system attacks and destroys healthy tissue. This condition causes inflammation, swelling, and irritation in blood vessels and other tissues. […] Most people with GPA can be treated. However, the medicines used to treat this condition could have side effects of their own. Be sure to talk about benefits and side effects with your healthcare provider. […] These are common medicines used in treatment: Corticosteroids. This steroid helps reduce inflammation. Long-term steroid use can affect your bone health, so your healthcare provider may also watch and treat changes in your bone density. Other possible side effects may include high blood pressure, diabetes, fluid retention, and mood swings.

• #54 New Granulomatosis with polyangiitis (Werner’s) treatments 2025 | Everyone.org

  https://everyone.org/explore/treatment/?id=45

  In addition to immunosuppressive treatments, supportive therapies play a crucial role in managing GPA complications and improving patient quality of life. These may include antibiotics for infection prevention, antihypertensive medications to manage blood pressure, bone protective agents to prevent osteoporosis, and nutritional support to maintain overall health. Regular monitoring and management of potential treatment-related complications, such as infections, cardiovascular disease, and malignancies, are essential components of comprehensive GPA care.

• #55 Granulomatosis with polyangiitis – Knowledge @ AMBOSS

  https://www.amboss.com/us/knowledge/granulomatosis-with-polyangiitis/

  Indication: patients with active disease […] Nonsevere disease: Glucocorticoids PLUS a glucocorticoid-sparing agent, e.g., methotrexate (preferred) or azathioprine […] Severe disease (i.e., organ- or life-threatening): Glucocorticoids PLUS a glucocorticoid-sparing agent, e.g., rituximab; (preferred) or cyclophosphamide. […] Indication: patients who initially presented with severe disease […] Slowly taper glucocorticoids to the minimum effective dose. […] Assessment for concurrent immunosuppressive states (e.g., HIV, TB, diabetes mellitus) is required before starting immunosuppressive therapy. […] Prevent complications of glucocorticoid therapy. […] Monitor for adverse effects of immunosuppressants. […] Consider pneumocystis pneumonia prophylaxis.

• #56 Favorable Pregnancy Outcome in a Granulomatosis With Polyangiitis Patient With Renal Insufficiency | Verma | Journal of Medical Cases

  https://www.journalmc.org/index.php/JMC/article/view/3610/2946

  Favorable Pregnancy Outcome in a Granulomatosis With Polyangiitis Patient With Renal Insufficiency […] To present a case of successful pregnancy outcome in a granulomatosis with polyangiitis (GPA) patient with renal insufficiency. GPA, formerly known as Wegeners granulomatosis, is a rare necrotizing systemic vasculitis, presenting with classical clinical triad of manifestations involving upper and lower airway and glomerulonephritis. Pregnancy with GPA is burdened with the risk of possible maternal and fetal complications, further leading to higher morbidity and mortality rate. Due to sparsity of studies of GPA in pregnancy, management needs to be individualised. Diagnostic workup should include serological markers, radiological and histopathological examination. Cyclophosphamide combined with prednisolone is the standard induction regimen. The unpredictable disease course and complications at unexpected gestation appears to be a major variable to take into account when assessing the risk of pregnancy with GPA. Early diagnosis, monitoring and timely intervention resulted in favourable pregnancy outcome in our patient.

• #57 Favorable Pregnancy Outcome in a Granulomatosis With Polyangiitis Patient With Renal Insufficiency | Verma | Journal of Medical Cases

  https://www.journalmc.org/index.php/JMC/article/view/3610/2946

  Pregnancies occurring in active disease or pregnancies complicated by new-onset disease or recurrent disease have a documented unfavorable maternal and perinatal outcome. However, pregnancies occurring during remission also seem to be associated with increased risk of complications. Disease activity can be assessed according to Birmingham Vasculitis Activity Score (BVAS), which scores nine organ systems for new or worse vasculitic findings. Remission is defined as BVAS 1 for 6 month on prednisolone 10 mg per day. Remission could be either on drug or drug-free. Remission in GPA was a rarity until the introduction of regimens combining oral CYC with steroids. Although this combination increased the survival rates, yet the drug toxicity remained a vital challenge in management. After successful remission induction, guidelines recommend removing the initial immunosuppressive agent and starting a maintenance regimen with either AZA or methotrexate (MTX).

• #58 Favorable Pregnancy Outcome in a Granulomatosis With Polyangiitis Patient With Renal Insufficiency | Verma | Journal of Medical Cases

  https://www.journalmc.org/index.php/JMC/article/view/3610/2946

  Rituximab (RTX), a chimeric cluster of differentiation 20 (CD20) monoclonal antibody has also been used for induction of remission in GPA. GPA is well-known for frequent relapses. British Society of Rheumatology defines relapse as a disease that has been previously well controlled with or without drugs and has become active. Relapse is further classified as minor if there is increase of one or more new or worse minor items and no major BVAS items. Major relapse involves increase of one or more major BVAS item. […] Pregnancy in patients with GPA requires preconceptional planning, careful clinical judgment, and vigorous treatment of active disease. The best time to plan conception is a minimum of six months after entering remission. A multidisciplinary approach is necessary for the diagnosis and therapeutic treatment of GPA. Multiple relapses also occur in some patients. Substantial organ damage due to disease complications and adverse effects of treatment is known to occur, leading to long-term sequelae.

• #59 WEGENERONA: COVID-19 INDUCED GPA (GRANULOMATOSIS WITH POLYANGIITIS) VASCULITIS – SHM Abstracts | Society of Hospital Medicine

  https://shmabstracts.org/abstract/wegenerona-covid-19-induced-gpa-granulomatosis-with-polyangiitis-vasculitis/

  A 60-year-old female with a history of diabetes and a recent diagnosis of COVID-19 four weeks ago presented to the hospital with a persistent cough, fatigue, and poor appetite. […] On day 3 of her hospitalization, her creatinine increased up to 2.96mg/dl from 2.65mg/dl at the time of admission. […] Nephrology and Rheumatology recommended starting intravenous solumedrol 500mg once daily for COVID-19 induced glomerulonephritis and presumptive Granulomatosis with polyangiitis (GPA). […] She was started on rituximab with gradual improvement in her renal functions. […] Early diagnosis of GPA can be difficult and requires a high index of suspicion in all patients, but especially in cases with atypical presentation. Prompt diagnosis and appropriate management of GPA in patients previously infected or co-infected with COVID-19 is essential to reduce morbidity and mortality.

• #60 Granulomatosis with Polyangiitis (GPA) – Johns Hopkins Vasculitis Center

  https://www.hopkinsvasculitis.org/types-vasculitis/granulomatosis-with-polyangiitis/

  Whenever possible, it is important to confirm the diagnosis of Granulomatosis with Polyangiitis by biopsying an involved organ and finding the pathologic features of this disease under the microscope. […] Lung biopsy (either open or thoracoscopic) is often the best way of diagnosing Granulomatosis with Polyangiitis. […] Until the 1970s, Granulomatosis with Polyangiitis was nearly always a fatal condition. […] The first use of cyclophosphamide in the late 1960s began to change the terrible prognosis of this disease. Using the combination of cyclophosphamide and prednisone, more than 90% of patients with severe disease respond to treatment, and 75% are able to achieve disease remissions. […] During the 1990s, physicians have increasingly used the combination of methotrexate and prednisone rather than cyclophosphamide and prednisone for Granulomatosis with Polyangiitis patients who do not have immediately life-threatening disease.

• #61 Granulomatosis with Polyangiitis (GPA) | STROKE MANUAL

  https://www.stroke-manual.com/granulomatosis-with-polyangiitis-gpa/

  the duration of maintenance therapy is usually 12-24 (36) months […] oral corticosteroids + methotrexate, azathioprine, or rituximab are used […] the choice of maintenance therapy is determined based on the patients individual response to treatment and their specific risk factors and comorbidities […] prognosis depends on the degree of renal impairment and whether therapy is initiated early […] early initiation of therapy can significantly improve the prognosis; 80-90% of patients survive 5 years and are able to lead a relatively normal life […] untreated disease has a poor prognosis; up to 70% of patients die within 1 year […] granulomatosis is prone to relapses; which can occur in up to 50% of patients, sometimes several years after the initial diagnosis; relapses may be triggered by infections or reductions in corticosteroid doses.

• #62 Granulomatosis with polyangiitis (GPA): Symptoms, causes, and more

  https://www.medicalnewstoday.com/articles/187807

  Granulomatosis with polyangiitis (GPA), previously known as Wegeners granulomatosis, is a rare and life-threatening disorder that restricts the blood flow to several organs, including the lungs, kidneys, and upper respiratory tract. […] GPA requires long-term immunosuppression. Some patients die due to the toxicity of the treatment. […] GPA is part of a larger group of vasculitic syndromes. […] The physician will ask about signs and symptoms, conduct a physical exam, and study the patients medical history. […] Treatment for GPA is usually divided into two stages: The induction of disease remission, which involves getting rid of all the signs and symptoms. […] Many drugs used to treat this condition weaken the patients immune system, so it is important to monitor the patient. […] Some patients may need surgery. If kidney failure occurs, the doctor may recommend a kidney transplant. […] Complications usually result from a lack of treatment. […] When GPA is fatal, this is normally because of kidney failure.

• #63 Granulomatosis with Polyangiitis (GPA): Causes, Symptoms, and Remedies

  https://resources.healthgrades.com/right-care/vascular-conditions/granulomatosis-with-polyangiitis

  GPA typically requires maintenance therapy for a few years. If your symptoms return and you have not been receiving rituximab, the 2021 treatment guidelines endorsed by the American College of Rheumatology and the Vasculitis Foundation recommend rituximab for further remission. Cyclophosphamide can be toxic if taken over long periods of time. […] The outlook for people with GPA varies depending on the severity of the disease, which organs it is affecting, and any complications resulting from the disease itself or its treatment. […] GPA is not currently curable, but remission is possible. Treatment is essential for extending the life expectancy of someone with GPA. On average, people with GPA who do not receive treatment live for 5 months after diagnosis. […] Recent advances in treatment have led to longer life expectancies for people with GPA. Researchers estimate that 80% of people who receive treatment live at least another 8–9 years. […] To diagnose GPA, doctors typically use imaging tests, blood and urine tests, and biopsies. Treatment involves taking medications that suppress the immune system and reduce inflammation, as well as undergoing plasma exchange.

• #64 Granulomatosis with Polyangiitis (GPA) – EyeWiki

  https://eyewiki.org/Granulomatosis_with_Polyangiitis_(GPA)

  Upon achieving a significant response (prior to remission) with the above treatment, one should begin tapering the dose of glucocorticoids. […] For maintenance of remission, rituximab, azathioprine, and methotrexate are the recommended options. […] Prior to immunosuppressive therapy, GPA was fatal with a mean survival rate of 5 months, when left untreated. With corticosteroid therapy alone, the mean survival increased to 12.5 months. […] Traditional therapies of combination prednisone and cyclophosphamide result in 90% of patients experiencing some symptomatic improvement and remission in 75%.

• #65 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/sites/books/NBK557827/

  Living with GPA can be extremely challenging. Patients often face fatigue, pain, disease-related complications, medication side effects, and emotional stress, all of which can significantly impact their well-being, work, and personal relationships. […] Due to the multisystemic nature of GPA, patients typically require care from multiple healthcare providers, making it crucial to adhere to follow-up appointments and treatment plans.

• #66 Granulomatosis with Polyangiitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/granulomatosis-with-polyangiitis/

  Living with a chronic disease such as GPA can be challenging at times. Fatigue, pain, emotional stress, and medication side effects can take a toll on your sense of well-being, affecting relationships, work, and other aspects of your daily life. […] There is no cure for GPA at this time, but early diagnosis and effective treatment can bring the disease into remission, and many patients can lead full, productive lives. Left untreated, GPA can lead to potentially life-threatening organ damage or failure. Even with treatment, many patients will experience periods of relapse, so ongoing medical care is important.

• #67 Granulomatosis with polyangiitis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/granulomatosis-with-polyangiitis/diagnosis-treatment/drc-20351093

  Diagnosis involves the steps that your healthcare team takes to find out if you have granulomatosis with polyangiitis (GPA). Your healthcare professional asks you about your symptoms and health history. You also get a physical exam. You may need other tests as well. […] Treatment for granulomatosis with polyangiitis (GPA) includes medicines to get the disease under control and keep it from coming back. Along with getting care from your regular healthcare professional, you’ll likely need treatment and follow-up care from various specialists. The specialists that you need depend on the organs that the disease affects. With early treatment, many people who have GPA get better and lead full lives. […] You’re likely to get better after treatment for granulomatosis with polyangiitis (GPA). Even so, you might feel stress about the disease coming back or the damage it can cause. Here are some tips to help you cope: Understand your condition. Learn all that you can about GPA. The knowledge may help you deal with complications, medicine side effects and relapses. Talk with your healthcare professional. You also might want to talk with a counselor or a medical social worker. […] A specialist likely will be the one to find out if you have granulomatosis with polyangiitis.

• #68

  https://arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/granulomatosis-with-polyangiitis-(gpa)

  Physiotherapy, occupational therapy, regular exercise and relaxation techniques are very important parts of your overall treatment plan. […] Learning as much as you can about the disease is also important to help you make informed decisions about treatment and lifestyle, and maximize your quality of life.

• #69 Granulomatosis with polyangiitis | UM Health-Sparrow

  https://www.uofmhealthsparrow.org/departments-conditions/conditions/granulomatosis-polyangiitis

  Treatment for granulomatosis with polyangiitis (GPA) includes medicines to get the disease under control and keep it from coming back. Along with getting care from your regular healthcare professional, you’ll likely need treatment and follow-up care from various specialists. […] With early treatment, many people who have GPA get better and lead full lives. […] Medicines called corticosteroids help lessen the immune system response and lower inflammation of the blood vessels. […] Once your condition is under control, you might stay on some medicines long-term. […] You’re likely to get better after treatment for granulomatosis with polyangiitis (GPA). Even so, you might feel stress about the disease coming back or the damage it can cause. […] A specialist likely will be the one to find out if you have granulomatosis with polyangiitis.

• #70 Granulomatosis with Polyangiitis | Rheumatology & Clinical Research located in North Houston, Tomball, TX | Rheumatology Clinic of Houston

  https://www.houstonrheumatology.com/content/granulomatosis-with-polyangiitis

  Significant side effects of medications used to treat GPA can be minimized with preventive strategies. […] While disease relapses frequently occur, early detection and treatment can lessen the potential for serious organ injury. […] Depending on the organ sites involved, people with GPA frequently require care from numerous physician specialists, each of whom contributes in a valuable way. Within this working team, however, it remains important to identify a specific doctor to prescribe and check for problems with related medications. This is typically the rheumatologist who is trained to use these medications to effectively treat GPA while minimizing the potential for side effects.

• #71 Granulomatosis with Polyangiitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/granulomatosis-with-polyangiitis/

  Living with a chronic disease such as GPA can be challenging at times. Fatigue, pain, emotional stress, and medication side effects can take a toll on your sense of well-being, affecting relationships, work, and other aspects of your daily life. […] There is no cure for GPA at this time, but early diagnosis and effective treatment can bring the disease into remission, and many patients can lead full, productive lives. Left untreated, GPA can lead to potentially life-threatening organ damage or failure. Even with treatment, many patients will experience periods of relapse, so ongoing medical care is important.

Zobacz więcej